Chronic Myeloid Leukemia (BCR-ABL1) · line 1 · 2nd-generation TKI (dasatinib OR nilotinib OR bosutinib by comorbidity matrix) — CML chronic phase 1L for high-risk / younger seeking TFR
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-2GEN-TKI-CML |
| ID | IND-CML-1L-2GEN-TKI |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CML |
| Sources | SRC-ELN-CML-2020 SRC-ESMO-CML-2017 SRC-NCCN-MPN-2025 |
Notes
AGGRESSIVE track for CML 1L with TFR ambition or high-risk biology. Selection between dasatinib / nilotinib / bosutinib / asciminib done via comorbidity sub-matrix at the regimen level. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-CML-1L- ALGO-CML-1LALGO-CML-2L- ALGO-CML-2L